⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1443759 | 0.94 | — | — | |
| SCHEMBL1443803 | 0.93 | — | — | |
| SCHEMBL1444039 | 0.93 | — | — | |
| Ibezapolstat SCHEMBL15908884 | 0.93 | — | — | |
| Ibezapolstat SCHEMBL29357391 | 0.93 | — | — | |
| SCHEMBL1443265 | 0.92 | — | — | |
| SCHEMBL12173570 | 0.92 | — | — | |
| Ibezapolstat SCHEMBL15908913 | 0.92 | — | — | |
| SCHEMBL1443301 | 0.92 | — | — | |
| Hydrochloric Acid SCHEMBL15909144 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796292-B2 | Selective antibacterials for clostridium difficile infections | GLSYNTHESIS INC. (US) | 2014-08-05 | — | — | US | claimed |
| US-20120232077-A1 | SELECTIVE ANTIBACTERIALS FOR CLOSTRIDIUM DIFFICILE INFECTIONS | ACURX PHARMACEUTICALS, LLC | 2012-09-13 | — | — | US | claimed |
| EP-2475252-A1 | SELECTIVE ANTIBACTERIALS FOR CLOSTRIDIUM DIFFICILE INFECTIONS | Glsynthesis Inc. (US) | 2012-07-18 | — | — | EP | claimed |
| WO-2011031935-A1 | SELECTIVE ANTIBACTERIALS FOR CLOSTRIDIUM DIFFICILE INFECTIONS | GLSYNTHESIS INC. (US) | 2011-03-17 | — | — | WO | claimed |
| EP-2475252-B1 | SELECTIVE ANTIBACTERIALS FOR CLOSTRIDIUM DIFFICILE INFECTIONS | GLSYNTHESIS INC (US) | 2016-11-16 | — | — | EP | disclosed |
| US-8796292-B2 | Selective antibacterials for clostridium difficile infections | GLSYNTHESIS INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796292-B2 | Selective antibacterials for clostridium difficile infections | GLSYNTHESIS INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796292-B2 | Selective antibacterials for clostridium difficile infections | GLSYNTHESIS INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120232077-A1 | SELECTIVE ANTIBACTERIALS FOR CLOSTRIDIUM DIFFICILE INFECTIONS | ACURX PHARMACEUTICALS, LLC | 2012-09-13 | — | — | US | disclosed |
| US-20120232077-A1 | SELECTIVE ANTIBACTERIALS FOR CLOSTRIDIUM DIFFICILE INFECTIONS | ACURX PHARMACEUTICALS, LLC | 2012-09-13 | — | — | US | disclosed |
| US-20120232077-A1 | SELECTIVE ANTIBACTERIALS FOR CLOSTRIDIUM DIFFICILE INFECTIONS | ACURX PHARMACEUTICALS, LLC | 2012-09-13 | — | — | US | disclosed |